Accura Animal Health is a pharmaceutical and diagnostics company focused on the animal health market and is divided into two core divisions: Animal Health Pharmaceuticals and Animal Health Diagnostics.

Animal Health Pharmaceuticals is focused on the development, manufacture and commercialisation of pharmaceuticals aimed at improving the quality of life and maintaining the health of companion animals.

Accura Animal Health Diagnostics has novel diagnostic products in the fields of animal health screening and mastitis detection in dairy cows.  Two primary product groups have been sold collectively in over 30 countries globally since May 2007.  The products are stable, proven, and poised for significant growth.

Business model

The strategic value proposition for Accura centres around three key pillars in its business model.  

University-based Innovation
By utilising university based innovation, Accura captures the maximum upside potential with a low-risk, low-cost of entry.   Accura believes that leveraging academic and institutional based research and facilities provides a key competitive advantage allowing for validation of the technology (i.e. pre-clinical work and some clinical data in the target animal species) within a controlled university environment.  This eliminates the need for Accura to assemble capital intensive facilities and staff, keeping a nimble development organisation able to rapidly capitalise on industry and market trends. 

Market-Driven Development 
Accura starts with a known and expanding market need and sources market-ready technologies that have an applied prototype or proof of concept to meet this need.  This model defers much of the true R&D time and costs, including the costs related to initial patent protection, to the university or development partners prior to Accura’s involvement.
 Accura’s approach is market-need driven, not “supply” driven. This ultimately provides a more rapid product adoption cycle once a drug enters the market place and a reduced cost in “educating” the practitioner (vet).
  
Maximised Capital Efficiency
Accura looks to capital efficiency as a driver for shareholder value creation.  This can be seen in creating lean drug development costs (i.e. leveraging university partner infrastructure to lower costs), minimising time to market for new products or drugs (i.e. market-ready technology and cross-over drug development in animal health) and a performance-based funding model (i.e. drug development funding is broken down into measured, success-based milestones). 

These three pillars working together create a strong foundation from which Accura can grow and build.  Core to Accura’s effective portfolio management begins with the Organisation’s technology identification and selection.  Accura employs a methodical and structured approach to both technology selection and development.  All technology within the portfolio must meet the following characteristics: 

• Robust and easily communicated scientific backbone
• Development rationale is underpinned by a significant differentiating point
• The Product can be targeted at a strong, growing and newsworthy market
• Initial IP and Patent position can be expanded as the Product develops
• Target market is not yet over competitive
• Clear and achievable Regulatory route
  Low manufacturing cost
• Value Inflection Points within 18 & 36 month windows
• Multiple milestone-driven news worthy events within 36 months
• Clear route of Product exit through licensing to large sales and marketing partners or improving M&A prospects